---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-045601"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:52:34.961600+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics Q2 2022 net loss $8.5M ($0.80/share); cash $112.8M

## Summary
- Net loss of $8.5M ($0.80 per share) vs $12.8M ($1.14) in Q2 2021.
- Cash, cash equivalents and marketable debt securities of $112.8M as of June 30, 2022.
- R&D expenses decreased to $3.1M from $5.9M; G&A decreased to $5.6M from $6.9M.
- ADVANCED-1 Phase 1 trial of TARA-002 in NMIBC enrollment progressing; Trials in Progress poster presented at ASCO June 2022.
- EMA granted orphan drug designation to TARA-002 for lymphatic malformations; Phase 2 trial planned.

## SEC filing metadata
- accession: 0001213900-22-045601
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390022045601/0001213900-22-045601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390022045601/ea163937-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-045601
- JSON: https://secwatch.observer/filing/0001213900-22-045601.json
- Plain text: https://secwatch.observer/filing/0001213900-22-045601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.